sector medic suppli devic
 strong momentum upcom catalyst
ramp profit upgrad buy
messag warm cours year
hope good great might provid attract entri point head
catalyst-rich instead report truli remark quarter sale
yoy top consensu oper margin expand
full vs expect stock sharpli tomorrow see
much like stori right stay sidelin result
upgrad neutral buy establish price target
base multipl forward ntm sale forecast
outstand momentum hand potenti increment catalyst set
come fold next quarter see well-posit
sustain top tier growth beyond ever quarter compani
perform fall bit would anniversari
launch deal distract one manufactur line go offlin
septemb instead growth actual acceler alreadi robust level driven
particularli impress quarter domest believ moder
torrid trajectori inevit see number increment catalyst next
month support continu top tier growth includ launch
medicar popul kick last month fda approv control-iq
algorithm expans japan fda approv horizon
close loop system limit launch sensor late next year ahead
broader roll-out
innov come backdrop rapidli increas adopt
diabet technolog doubl estim cgm market
track grow anoth number patient therapi
compar two year ago pump market also show sign
acceler growth ahead wave improv autom insulin deliveri system set
come market next year success libr play
key role democrat cgm technolog remain gold standard real-tim
glucos measur prefer partner pump smart pen manufactur
attempt revolution insulin deliveri see dynam propel
revenu growth
meanwhil compani becom much top-lin growth stori
perhap impress part quarter leverag abl
drive oper margin expand nearli yoy
come well ahead consensu forecast compani achiev
improv profit despit gross margin actual miss street estim
sg expens declin sequenti even ad sale
vs expect spend pick bit manag invest
support futur growth progress compani made date suggest us
could approach goal oper margin soon next year
turn back quarter busi continu fire cylind
domest sale top street expect growth acceler
despit difficult comparison due lap last year
launch continu make steadi progress shift busi pharmaci
channel manag highlight new partnership walgreen
allow medicar patient fill prescript local pharmaci
often trade-off improv market access term price concess thu far
exchang seem play decis favor
page analyst certif import disclosur
elsewher intern busi also turn strong perform
ou revenu beat grew cc particularli difficult yoy
comp product level basi global sensor sale
came consensu drove upsid quarter hardwar sale
mix beat transmitt off-set miss
receiv go forward expect hardwar growth continu
lag behind sensor promot broader access hardwar rebat
pharmaci channel longer term transit featur integr sensor/
transmitt fulli dispos increas use mobil app rather dedic
receiv like put addit pressur hardwar compon
top line strong opex manag off-set gm pressur contribut
sharp step profit report gross margin
yoy consensu manag also lower full year gm guidanc
disrupt caus one compani product line go
offlin septemb expect result slower transit certain
channel elsewher sg expens rose yoy sale
street estim meanwhil spend increas yoy revenu
consensu except oper leverag result ebit
margin improv yoy ahead consensu combin drove
net incom per share vs street per share forecast
guidanc head higher back result manag rais
revenu outlook third time year call full year sale rise
vs previous updat guidanc reflect
anticip product constraint result aforement manufactur line
issu elsewher compani expect oper margin come vs
previous ebitda forecast sale
model call post adjust ep total revenu
cc compar prior estim
respect long-term model grow clip
combin improv profit believ outlook warrant premium valuat
price target base multipl revis forward ntm sale
estim signific upsid potenti target current level upgrad
share neutral buy
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow recent fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point in-tim
blood glucos test reduc critic factor manag diabet
yet adopt technolog ramp slowli held back inconsist sensor accuraci
conveni qualiti life issu high increment cost therapi recent
advanc address mani histor drawback pave way rapidli
increas cgm penetr past two year
increasingli bullish long-term outlook cgm adopt
abil sustain leadership posit market best-in-class technolog coupl
improv patient access result sustain growth high end med-tech
sector model grow revenu clip driven strong
underli market growth continu transit pharmaci channel
expans new intern market expect launch new autom
insulin deliveri technolog key technolog partner
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim current trade ntm
sale toward low end rang comp group long-term
model grow clip combin improv profit
believ outlook warrant premium valuat upgrad share
neutral buy price target base multipl
forward ntm sale estim
downsid risk rate includ unexpect deceler cgm market growth
recent penetr gain greater anticip adopt competit cgm
technolog increment price pressur reduc sale margin
clinic regulatori setback key pipelin program particular sensor
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
